Skip to main content
SpringerLink
Log in

Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy

  • Part II: Cardiac Hypertrophy and Failure
  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Numerous studies suggest that the renin angiotensin system (RAS) is involved in the development of cardiac hypertrophy. In the present study we produced cardiac hypertrophy in rats subjected to abdominal aortic banding and also induced cardiac regression by the administration of an angiotensin converting enzyme (ACE) inhibitor, enalapril, at 3, 10 and 30 mg/kg/day. Each drug was administered to the rats for 6 weeks from 6 weeks after aortic banding. The left ventricular weight significantly decreased at 10 and 30 mg/kg/day of enalapril as well as the systolic blood pressure. Using the reverse transcriptase polymerase chain reaction, the increased levels of ACE and AT1 mRNA were significantly inhibited in the aortic banding rats treated with the above concentrations of enalapril. The ACE activity in both the plasma and heart tissue preparations was significantly inhibited by enalapril. Similar observations were also seen after the administration of angiotensin type 1 receptor blockade, E-4177, into the aortic banding rats. The treatment with enalapril at 3 mg/kg/day did not reduce the left ventricular weight or the systolic blood pressure in the aortic banding rats. However, this low-dose treatment did significantly decrease the left ventricle to body weight ratio in the aortic banding rats without a reduction of the systolic blood pressure. Therefore, using the low-dose enalapril, the ACE activity in plasma was in part inhibited and the levels of ACE mRNA also decreased in the heart tissue of aortic banding rats, while the level of AT1 mRNA showed no such decrease. These results thus indicate that chronic ACE inhibitor at low doses has a beneficial effect on the regression in the pressure-induced cardiac hypertrophy. It is thus assumed that this effect may also contribute to the presence of an alternate pathway for the conversion of angiotensin I to angiotensin II which might also act as a possible mechanism for cardiac regression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baker KM, Booz GW, Dostal DE: Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Ann Rev Physiol 54: 227–241, 1992

    Article  Google Scholar 

  2. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE: A comparative study of the distribution of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissue. Endocrinology 120: 2334–2339, 1987

    PubMed  Google Scholar 

  3. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest, 36: 1913–1920, 1990

    Google Scholar 

  4. Baker KM, Aceto JF: Angiotensin II stimulation of protein synthesis and cell growth in chick heart cell. Am J Physiol 259: H610- H618, 1990

    PubMed  Google Scholar 

  5. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM: Angiotensin II is miotogenic in neonatal rat cardiac fibroblast. Circ Res 72: 1245–1254, 1993

    PubMed  Google Scholar 

  6. Linz W, Scholkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens Part A Theory Pract 11: 1325–1350, 1989

    Google Scholar 

  7. Makino N, Matsui H, Masutomo K, Hata T, Yanaga T: Effect of angiotensin converting enzyme inhibitor on regression in cardiac hypertrophy. Mol Cell Biochem 119: 23–28, 1993

    PubMed  Google Scholar 

  8. Unger T, Mattfeldt T, Lamberty V, Bock P, Linz W, Scholkens BA, Gohlke P: Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 20: 478–482, 1992

    PubMed  Google Scholar 

  9. Zierhut W, Zimmer H-G, Gerdes AM. Effects of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res 69: 609–617, 1991

    PubMed  Google Scholar 

  10. Hirakata H, Fouad-Tarazi FM, Bumpus FM, Khosi M, Healy B, Husain A, Urata H, Kunagai: Angiotensins and the failing heart enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril. Circ Res 66: 891–899, 1990

    PubMed  Google Scholar 

  11. Linz W, Scholkens BA: A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 105: 771–772, 1992

    PubMed  Google Scholar 

  12. Gohlke P, Unger T: Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin. Am J Cardiol 76: 41E-45E, 1995

    Article  PubMed  Google Scholar 

  13. Nakanishi H, Makino N, Hata T, Matsui H, Yano K, Yanaga T: Sarcolemmal Ca2+ transport activities in cardiac hypertrophy caused by pressure overload. Am J Physiol 257 (Heart Circ Physiol 26): H349-H356,1989

    PubMed  Google Scholar 

  14. Okunishi H, Song K, Oka Y, Kobayashi T, Kawamoto T, Ishihara H, Mori N, Miyazaki M: In vitro pharmacology of a novel non-peptide angiotensin II -receptor antagonist, E-4177. Jap J Pharmacol 62: 239–244, 1993

    PubMed  Google Scholar 

  15. Hayakari M, Kondoh Y, Ihumi H: A rapid and simple spectrophotometric assay of angiotensin-converting enzyme. Anal Biochem 84: 361–369, 1978

    PubMed  Google Scholar 

  16. Makino N, Hata T, Sugano M, Dixon IMC, Yanaga T.Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats. J Mol Cell Cardiol 28: 507–517, 1996

    PubMed  Google Scholar 

  17. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE: Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature (London) 351: 233–236, 1991

    Google Scholar 

  18. Fort Ph, Marty I, Piechaczyk M, Sabrouty SEI, Dani CH, Jeanteur Ph, Blanchard JM: Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family Nucleic Acids Research. 13: 1431–1442, 1985

    PubMed  Google Scholar 

  19. Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Linz W, Scholkens BA, Wiemer G, Unger T: Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3¢,5¢-monophosphate. Hypertension 22: 682–687, 1993

    PubMed  Google Scholar 

  20. Wiemer G, Scholkens BA, Becker RHA, Busse R: Ramiprillart enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 18: 558–563, 1991

    PubMed  Google Scholar 

  21. Kojima M, Shiojima I, Yamazaki T, Komuro I, Yunzeng Z, Ying W, Mizuni T, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y: Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocytes hypertrophy in vitro. Circulation 89: 2204–2211, 1994

    PubMed  Google Scholar 

  22. Ruzicka M, Yuan B, Leenen FHH. Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation 90: 484–491, 1994

    PubMed  Google Scholar 

  23. Ruzicka M, Yuan B, Hermsen E, Leenen FHH: The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation 87: 921–930, 1993

    PubMed  Google Scholar 

  24. Suzuki J, Matsubara H, Urakami M, Inada M: Rat angiotensin II (type IA) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 73: 439–447, 1993

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bioclimatology and Medicine, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, 874, Beppu, Japan

    Naoki Makino, Masahiro Sugano, Tomoji Hata, Sachiyo Taguchi & Takashi Yanaga

Authors
  1. Naoki Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Sugano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomoji Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sachiyo Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Yanaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Makino, N., Sugano, M., Hata, T. et al. Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy. Mol Cell Biochem 163, 239–245 (1996). https://doi.org/10.1007/BF00408664

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00408664

Key words

Search

Navigation